Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)
Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –
Exelixis gross margin
Gross margin is gross profit as a percentage of revenue.
Exelixis's gross margin for the twelve months ending Oct 2, 2026 was 96.3%. For fiscal 2025 it was 96.4%, against 96.5% the year before. The highest annual figure on record is 100.0% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Jan 2, 2026 | 96.4% | −0.1 |
| FY2024 | Jan 3, 2025 | 96.5% | +0.4 |
| FY2023 | Dec 29, 2023 | 96.0% | −0.4 |
| FY2022 | Dec 30, 2022 | 96.4% | +0.1 |
| FY2021 | Dec 31, 2021 | 96.3% | −0.0 |
| FY2020 | Jan 1, 2021 | 96.3% | −0.3 |
| FY2019 | Jan 3, 2020 | 96.6% | −0.3 |
| FY2018 | Dec 28, 2018 | 96.9% | +0.2 |
| FY2017 | Dec 29, 2017 | 96.7% | +0.1 |
| FY2016 | Dec 31, 2016 | 96.6% | +7.1 |
| FY2015 | Dec 31, 2015 | 89.5% | −2.3 |
| FY2014 | Dec 31, 2014 | 91.9% | −4.6 |
| FY2013 | Dec 31, 2013 | 96.4% | −3.6 |
| FY2012 | Dec 31, 2012 | 100.0% | +0.0 |
| FY2011 | Dec 31, 2011 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Oct 2, 2026 | 96.0% | −0.9 |
| Q2 FY2026 | Jul 3, 2026 | 96.7% | +0.1 |
| Q1 FY2026 | Apr 3, 2026 | 96.7% | +0.2 |
| Q4 FY2025 | Jan 2, 2026 | 95.6% | −0.9 |
| Q3 FY2025 | Oct 3, 2025 | 96.9% | +0.1 |
| Q2 FY2025 | Jul 4, 2025 | 96.6% | −0.7 |
| Q1 FY2025 | Apr 4, 2025 | 96.5% | +1.5 |
| Q4 FY2024 | Jan 3, 2025 | 96.5% | +1.0 |
| Q3 FY2024 | Sep 27, 2024 | 96.8% | +0.8 |
| Q2 FY2024 | Jun 28, 2024 | 97.2% | +1.0 |
| Q1 FY2024 | Mar 29, 2024 | 95.0% | −1.5 |
| Q4 FY2023 | Dec 29, 2023 | 95.5% | −0.8 |
| Q3 FY2023 | Sep 29, 2023 | 96.0% | −0.3 |
| Q2 FY2023 | Jun 30, 2023 | 96.2% | −0.6 |
| Q1 FY2023 | Mar 31, 2023 | 96.5% | +0.2 |
| Q4 FY2022 | Dec 30, 2022 | 96.2% | −0.9 |
| Q3 FY2022 | Sep 30, 2022 | 96.3% | −0.1 |
| Q2 FY2022 | Jul 1, 2022 | 96.8% | +0.7 |
| Q1 FY2022 | Apr 1, 2022 | 96.3% | +1.2 |
| Q4 FY2021 | Dec 31, 2021 | 97.1% | +26.3 |
| Q3 FY2021 | Oct 1, 2021 | 96.4% | +27.2 |
| Q2 FY2021 | Jul 2, 2021 | 96.1% | +30.8 |
| Q1 FY2021 | Apr 2, 2021 | 95.1% | +13.8 |
| Q4 FY2020 | Jan 1, 2021 | 70.8% | −5.9 |
| Q3 FY2020 | Oct 2, 2020 | 69.2% | +1.4 |
| Q2 FY2020 | Jul 3, 2020 | 65.3% | −12.1 |
| Q1 FY2020 | Apr 3, 2020 | 81.3% | +1.5 |
| Q4 FY2019 | Jan 3, 2020 | 76.7% | +2.9 |
| Q3 FY2019 | Sep 27, 2019 | 67.8% | −1.2 |
| Q2 FY2019 | Jun 28, 2019 | 77.5% | +2.3 |
| Q1 FY2019 | Mar 29, 2019 | 79.9% | +19.7 |
| Q4 FY2018 | Dec 28, 2018 | 73.9% | −2.3 |
| Q3 FY2018 | Sep 28, 2018 | 69.0% | +8.9 |
| Q2 FY2018 | Jun 29, 2018 | 75.1% | −10.7 |
| Q1 FY2018 | Mar 30, 2018 | 60.2% | −21.0 |
| Q4 FY2017 | Dec 29, 2017 | 76.2% | +11.7 |
| Q3 FY2017 | Sep 30, 2017 | 60.2% | – |
| Q2 FY2017 | Jun 30, 2017 | 85.8% | – |
| Q1 FY2017 | Mar 31, 2017 | 81.2% | – |
| Q4 FY2016 | Dec 31, 2016 | 64.5% | – |
See a number that looks wrong?